Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Diarrhea-Predominant Irritable Bowel Syndrome
Interventions: Glutamine; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 72 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 32
States / cities: Tempe, Arizona • Corona, California • Gardena, California + 28 more

Conditions: Infection, Surgery, Nervous System Diseases
Interventions: Vancomycin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Tetraplegia, Asthma
Interventions: N-Nitro L-arginine-methylester (L-NAME); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 2,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 254
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Portion-controlled diet, Usual Diet; Other · Dietary Supplement
Lead sponsor: Nutrisystem, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Giant Cell Arteritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more

Conditions: Diabetes Type 2, Overweight or Obesity
Interventions: App; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 40 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson's Disease
Interventions: Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 25 more

Conditions: Type 1 Diabetes
Interventions: Difluoromethylornithine, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 40 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Indianapolis, Indiana • Buffalo, New York • Wauwatosa, Wisconsin

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Chimeric Therapies; Industry
Eligibility: 12 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 15
States / cities: La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Type2 Diabetes Mellitus, Obesity
Interventions: 3:1 ratio Ketogenic diet; Other
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post-infectious Irritable Bowel Syndrome, Irritable Bowel Syndrome
Interventions: Not listed
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Persistent Allergic Asthma
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 50
States / cities: Jasper, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Regular Insulin, Humalog; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Contact Lens Wear
Interventions: ASP-57, ReNu® Multiplus; Device
Lead sponsor: Asepticys LLC; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 14
States / cities: Irvine, California • San Diego, California • Longwood, Florida + 11 more

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma
Interventions: Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine, Granulocyte Colony-Stimulating Factor (G-CSF); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 26
States / cities: Glendale, Arizona • Beverly Hills, California • Walnut Creek, California + 23 more

Conditions: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Interventions: Alintegimod, Ipilimumab, Nivolumab; Drug
Lead sponsor: 7 Hills Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions: G-Pen, Lilly Glucagon; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more

Conditions: Myoma
Interventions: Vasopressins; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 2
States / cities: Beachwood, Ohio • Cleveland, Ohio

Conditions: Idiopathic Membranous Nephropathy
Interventions: Rituximab, Cyclosporine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more

Conditions: Heart Transplantation
Interventions: Daclizumab, Methylprednisolone, Mycophenolate mofetil, Placebo, cyclosporine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 19 more

Conditions: Low Grade Glioma
Interventions: Vinblastine, Bevacizumab; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 6 Months to 18 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more

Search by objective public record fields.

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Topical Vancomycin for Neurosurgery Wound Prophylaxis

Exhaled Levels of Nitric Oxide

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Blood Glucose Stability and Variability on Two Diets

Abatacept for the Treatment of Giant Cell Arteritis

Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

DFMO in Children With Type 1 Diabetes

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Treatment of Type 2 Diabetes With Ketogenic Diet

Characterizing Protein Biomarkers of Post-infection Irritable Bowel Syndrome

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

A Safety and Effectiveness Study of a New Multi-Purpose Contact Lens Care Solution

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy

MEmbranous Nephropathy Trial Of Rituximab

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)